Search results for " Bisphosphonate"

showing 10 items of 40 documents

Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed

2014

AbstractRecent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exp…

MaleDelayed DiagnosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAntineoplastic AgentsOsteonecrosis; Jawbones; BisphosphonatesOsteonecrosis; Jawbones;BisphosphonatesSettore MED/29 - Chirurgia MaxillofaccialeSettore MED/28 - Malattie OdontostomatologicheOsteonecrosis; Jawbones; Bisphosphonates;JawbonesBisphosphonateHumansDiagnostic Errorsosteonecrosis; jawbones; bisphosphonatesPeriodontal DiseasesAgedPain MeasurementBone Density Conservation AgentsOsteonecrosisBisphosphonatesMiddle AgedCross-Sectional StudiesPhenotypeOtorhinolaryngologyTooth DiseasesTooth ExtractionOsteonecrosiOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOral SurgeryJawbone
researchProduct

Intravenous bisphosphonate-related osteonecrosis of the jaws: Influence of coadjuvant antineoplastic treatment and study of buccodental condition

2012

Objectives: To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to analyze the buccodental condition of these patients. Material and methods: The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiving treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the size (cm) and number of bone exposures were recorded. The data obtained were subjected to analys…

MaleMultivariate statisticsmedicine.medical_treatmentDentistryOdontologíaAntineoplastic AgentsLogistic regressionIntravenous bisphosphonatesmedicineHumansWhole salivaGeneral DentistryBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyDiphosphonatesbusiness.industryHealthy subjectsBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyChemotherapy AdjuvantUNESCO::CIENCIAS MÉDICASInjections IntravenousSurgeryResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleAnalysis of variancebusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Physiology of the aging bone and mechanisms of action of bisphosphonates.

2011

Fragility fractures, a major public health concern, are expected to further increase due to aging of the world populations because age remains a cardinal, independent determinant of fracture risk. With aging the balance between bone formation and resorption during the remodeling process becomes negative, with increased resorption and reduced formation. Bisphosphonates (BPs) are widely prescribed anti-resorptive agents that inhibit osteoclasts attachment to bone matrix and enhance osteoclast apoptosis. BPs can be divided into nitrogen-containing (N-BPs) and non-nitrogen-containing BPs (non-N-BPs). Both classes induce apoptosis but they evoke it differently. Several studies have examined the …

Malemedicine.medical_specialtyAgingSettore MED/09 - Medicina Internamedicine.medical_treatmentOsteoporosisurologic and male genital diseasesBone resorptionBone and BonesBone remodelingOsteoclastInternal medicinemedicineHumansCellular SenescenceBONE BONE TURNOVER FRAGILITY FRACTURES AGING BISPHOSPHONATESOsteoblastsBone Density Conservation AgentsDiphosphonatesbusiness.industryBone metastasisOsteoblastBisphosphonatemedicine.diseaseEndocrinologymedicine.anatomical_structureOsteocyteFemaleBone RemodelingGeriatrics and GerontologybusinessGerontologyhormones hormone substitutes and hormone antagonistsBiogerontology
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain

2011

Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain. Study Design:A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years. Results: We detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate [16 patients] and ibandronate [4 patients]), which were mainly…

Malemedicine.medical_specialtyOsteoporosisCorticosteroid treatmentDiabetes mellitusmedicineHumansStage (cooking)Ibandronic AcidGeneral DentistryAgedRetrospective StudiesAged 80 and overSeries (stratigraphy)Oral Medicine and PathologyOral bisphosphonatesAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryMedical recordMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASOral examinationBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis : a comparative study

2009

Aims: We analyze the possible clinical differences between bone jaw exposed areas in ONJ (osteonecrosis of the jaws) and ORN (osteoradionecrosis). Patients and method: Group 1 was composed with 53 ONJ cases and group 2 with 20 ORN cases. In both groups we analyzed, the major size of the exposed bone areas, the number of exposed areas, the location on the jaws and the presence of others associated and severe complications, such as skin fistulas and jaw fractures. We also investigated the possible local aetiology or trigger factor of the lesions. Results: The major size of the bone exposed areas was 2.29±2.02(mean ± std.dev) in group 1 and 2.7±2.9 (mean ± std.dev) in group 2 (p>0.05). The num…

Malemedicine.medical_specialtyOsteoradionecrosismedicine.medical_treatmentDentistryIntravenous bisphosphonatesCerebrospinal fluid fistulamedicineHumansInfusions IntravenousGeneral DentistryDiphosphonatesTrigger factorbusiness.industryOsteonecrosismedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryOsteoradionecrosisOtorhinolaryngologyDental extractionJaw FractureUNESCO::CIENCIAS MÉDICASEtiologyFemaleSurgerybusinessJaw Diseases
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Mevalonate pathway: role of bisphosphonates and statins.

2011

Mevalonate; statins; bisphosphonatesSettore MED/09 - Medicina InternaMevalonatestatinbisphosphonates
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct